Since the discovery of heterozygous mutations of the activin A receptor, type I (ACVR1) gene in 2006 and the subsequent establishment of the causative pathway of FOP [3], molecular testing has been used to confirm clinical diagnosis. The gene discussed is ACVR1; the disease is fibrodysplasia ossificans progressiva.